Overview

Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Alflutinib in Advanced Non Small Cell Lung Cancer

Status:
Active, not recruiting

Trial end date:
2020-08-30

Target enrollment:

Participant gender:

Summary

Alflutinib Mesylate Tablets is a Epidermal Growth Factor Receptor (EGFR) mutation selective Tyrosine Kinase Inhibitor which can efficient suppress the EGFR T790M drug-resistant mutation tumor cell in Xenograft mouse model. This study aims at local advanced or metastatic non-small cell lung cancer patients with T790M drug-resistant mutation.

Phase:

Phase 1

Details

Lead Sponsor:

Allist Pharmaceuticals, Inc.

Treatments:

Aflutinib